Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC

Next Previous
X
Search
Trial Profile

IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Threitolceramide 6 (Primary)
  • Indications Adenocarcinoma; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms IMP-MEL trial; IMPORT-201; KEYNOTE E69
  • Sponsors iOx Therapeutics

    • Most Recent Events

    • 22 Apr 2024 Status changed from suspended to discontinued to prioritize the other assets in the pipeline. There were no safety or efficacy issues.
    • 04 Jan 2024 Status changed from recruiting to suspended, according to a Portage Biotech media release.
    • 04 Jan 2024 According to a Portage Biotech media release, after a review of company's funding requirements, the Board of Directors has made a decision to pause further drug development in the PORT-2 iNKT program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top